Media coverage about TrovaGene (NASDAQ:TROV) has trended positive this week, AlphaOne Sentiment Analysis reports. The research firm, a unit of Accern, scores the sentiment of news coverage by monitoring more than twenty million news and blog sources. AlphaOne ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. TrovaGene earned a media sentiment score of 0.44 on AlphaOne’s scale. AlphaOne also assigned media stories about the medical research company an impact score of 0 out of 100, meaning that recent news coverage is extremely unlikely to have an impact on the stock’s share price in the near future.
These are some of the headlines that may have impacted Alpha One’s analysis:
- Maxim Group Kept TrovaGene (NASDAQ:TROV) As a “Buy”; They … – WeeklyHub (weeklyhub.com)
- Key Researchers at Maxim Group Reiterate their ‘Buy’ rating for TrovaGene (NASDAQ:TROV) Shares Today. Their … – Weekly Register (weeklyregister.com)
- Trovagene Signs Deal With AstraZeneca (sdbj.com)
- TROVAGENE, INC. : Submission of Matters to a Vote of Security Holders (form 8-K) (4-traders.com)
- TrovaGene’s (TROV) “Buy” Rating Reiterated at Maxim Group (americanbankingnews.com)
TrovaGene (NASDAQ TROV) traded down 0.3178% on Monday, reaching $0.9409. 322,325 shares of the company’s stock were exchanged. The firm has a 50 day moving average price of $0.82 and a 200 day moving average price of $1.57. The firm’s market cap is $29.14 million. TrovaGene has a one year low of $0.61 and a one year high of $5.98.
TROV has been the topic of several analyst reports. S&P Equity Research lifted their price target on shares of TrovaGene from $1.55 to $1.80 in a report on Friday, March 10th. Maxim Group set a $4.00 price objective on shares of TrovaGene and gave the company a “buy” rating in a research report on Thursday, May 25th. Zacks Investment Research cut shares of TrovaGene from a “buy” rating to a “hold” rating in a research report on Wednesday, March 15th. Cantor Fitzgerald set a $8.00 price objective on shares of TrovaGene and gave the company a “buy” rating in a research report on Saturday, March 18th. Finally, Piper Jaffray Companies cut shares of TrovaGene from a “neutral” rating to an “underweight” rating in a research report on Thursday, March 16th.
TrovaGene Company Profile
Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.
Receive News & Ratings for TrovaGene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene Inc. and related companies with our FREE daily email newsletter.